Form 4: Lyell COO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold 95 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc. (LYEL), reported a transaction involving the company's common stock.
• On November 10, 2025, Mr. Hill disposed of 95 shares of common stock at a price of $16.12 per share.
• The sale was an automatic transaction to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following this transaction, Mr. Hill beneficially owns 15,750 shares of Lyell Immunopharma common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale for tax purposes, which does not reflect a change in management's outlook on the company's prospects.

Positives

• The transaction was non-discretionary, executed automatically to satisfy tax withholding requirements, indicating a routine administrative event rather than a strategic divestment.

Negatives

• The transaction resulted in a reduction of 95 shares from the Chief Operating Officer's direct beneficial ownership.

Risks

• NA

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction for tax purposes and does not provide information directly related to broader industry trends or competitive positioning.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• The impact on shareholders is minimal, as this is a small, non-discretionary sale by an executive for tax purposes, not indicative of a change in company fundamentals or executive confidence.

Next Steps

• NA

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an executive to cover tax obligations related to vested equity. It does not signal any change in the company's operational performance, strategic direction, or the executive's long-term confidence, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Lyell Immunopharma, LYEL, Insider Transaction, Form 4, Stock Sale, Chief Operating Officer, Restricted Stock Units, Tax Withholding